Vir Biotechnology, Inc.

VIR·NasdaqGS·Healthcare
Compare
11.77+0.55 (+4.90%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close11.22
Open11.68
Day range11.1711.81
52-week range4.8212.19
Off day high−0.30%
Off 52-week high−3.45%
Volume2.43M
Avg. volume (3M)1.94M
Market cap1.99B
EPS (TTM)-1.76
Forward P/E-4.77
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.74
Shares outstanding169.22M
Short interest9.72% of float
Earnings dateNov 4, 2026
Analyst target21.00
Profit margin−83.00%

Against its peers

Compare in full ›
VIR BHVN ASMB VOR 2137.HK BINV.ST
Market cap 1.99B 2.30B 404.57M 1.24B 739.58M 246.77M
P/E (TTM) — — 19.1 0.1 — —
Forward P/E -4.8 -8.2 -7.7 -5.7 -2.0 -1.0
Price/book 2.1 -23.4 1.3 -9.0 0.3 1.2
Dividend yield — — — — — —
1-year change +129.88% +78.66% −36.33% −5.02% −44.59% −88.73%
Today +4.90% −2.37% −0.25% +1.31% 0.00% +4.60%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All VIR news ›
@PRNewswire·Positive

News from Virax BioLabs Group Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

news News from Virax BioLabs Group Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Oct 29, 2026,…

BayStreet.ca·Negative

Vor Bio Down on Q3 Results

Vor Bio (NASDAQ: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. “We ended…

markets.businessinsider.com·Positive

Vor Bio initiated with an Outperform at William Blair

William Blair initiated coverage of Vor Bio (VOR) with an Outperform rating and $58.82 fair value estimate. Vor is a biotechnology company focus... Vor Bio initiated with an Outperform at William Blair William Blair initiated coverage of…

From the 4Search news index, newest first.

In the news

44mentions in 30 days
38with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 44 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance